Breaking Finance News

Aptose Biosciences (NASDAQ:APTO) stock price target increased to $1.00, issued a research note today by Rodman & Renshaw

Yesterday Aptose Biosciences (NASDAQ:APTO) traded -2.13% lower at $1.13. The company’s 50-day moving average is $1.49 and its 200-day moving average is $1.28. The last closing price is down 9.75% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time period. 371,340 shares of the stock traded hands, up from an average trading volume of 296,380

In a report released on 06/08/2017 Rodman & Renshaw increased the stock price target of Aptose Biosciences (NASDAQ:APTO) to $1.00 indicating a possible downside of -0.12%.

Previously on Thursday November 17, 2016, Zacks Investment Research reported on Aptose Biosciences (NASDAQ:APTO) increased the target price from $0.00 to $1.00. At the time, this indicated a possible upside of 0.04%.

See Chart Below

Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences has a 52 week low of $0.78 and a 52 week high of $2.40 The company’s market cap is currently $0.

In addition to Rodman & Renshaw reporting its stock price target, a total of 3 brokers have issued a research note on the company. The average stock price target is $9.01 with 2 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences Inc. (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities. The Company develops therapeutics focused on epigenetic processes and signal transduction abnormalities at the edge of cancer research, coupled with companion diagnostics to identify the optimal patient population for its products. The Company's APTO-253 is a small molecule that can induce expression of the genes that codes for the Kruppel-like factor 4 (KLF4) master transcription factor and the p21 cell cycle inhibitor protein.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.